FDA-Approved Synthetic THC Left Seniors More Likely to Quit. Real Cannabis Kept Them in the Study — and in Less Pain.

A rigorous 500-patient study compared the drug pharma developed to the plant it was supposed to replace. The plant won.

By Maya Torres | March 27, 2026

Dronabinol has been on the American market since 1985. It’s a synthetic, oral version of THC — the molecule that makes cannabis effective for pain — developed at a time when the federal government needed something it could control, patent, and prescribe without ever acknowledging that the plant itself worked.

For forty years, it has been the FDA-approved answer to a question America refused to ask directly.

A new study from German researchers, published this month in the Journal of Pain Research, asked that question head-on. In one of the largest real-world evaluations of cannabis-based medicines in elderly patients ever conducted, plant-derived cannabis extracts outperformed dronabinol across every measure that matters to a person living in pain: pain disability scores, sleep quality, psychological well-being, overall quality of life — and the likelihood of staying on treatment long enough for it to work.

Patients on dronabinol were significantly more likely to drop out.

What the Study Actually Found

German researchers in Nürnberg assessed 484 patients aged 65 and older — all dealing with chronic or treatment-resistant pain — over 24 weeks. Participants were split into matched cohorts: one group taking CBD-dominant plant-derived extracts, the other taking dronabinol.

Both treatments produced what the researchers called “clinically relevant improvements” in pain and quality of life. That part is not surprising. Cannabis-based medicines have been accumulating evidence for years.

What’s striking is the gap between the two.

Patients on plant-derived extracts showed greater overall improvement on every outcome measure. They were also more likely to complete the 24-week study. The dronabinol group had a higher rate of adverse drug reactions leading to discontinuation — meaning patients on the synthetic version were more likely to stop treatment because it made them feel worse.

“CBD > THC being associated with more favorable outcomes,” the researchers concluded, in the careful language of peer-reviewed science. “These findings expand the limited evidence on the use of cannabis-based medicines in elderly patients and complement previous clinical and observational studies on cannabinoids in pain medicine.”

Translation: the real thing works better than the pharmaceutical copy. And for elderly patients, who are already managing complex medication regimens and are more sensitive to side effects, that difference isn’t academic. It’s the difference between staying in treatment and giving up.

Who This Affects

There are roughly 55 million Americans aged 65 and older. Chronic pain is among the most prevalent conditions in that population — affecting an estimated one in three older adults. Prescription opioids, which carry serious risks for elderly patients including falls, cognitive decline, and dependency, remain a standard treatment. Alternatives that are both effective and tolerable are not abundant.

Cannabis use among older Americans has been rising sharply. NORML reported last October that seniors are increasingly identifying as cannabis consumers — typically for medical purposes — and surveys show older adults hold broadly positive attitudes toward cannabis for health reasons. They are finding their own path to the plant whether the medical system guides them there or not.

What this study adds is rigorous, large-scale data on what form of cannabis-based treatment actually delivers results for this population. The answer is the same one patients have been reporting anecdotally for years: whole-plant medicine, not synthetic isolates.

The American Problem

Here is the part the study doesn’t say but doesn’t need to.

Germany legalized medical cannabis in 2017 and broader adult-use access in 2024. German researchers could run a 484-patient real-world evaluation of plant-derived cannabis because their healthcare system could actually prescribe it, track outcomes, and follow patients over 24 weeks. Their data exists because access existed.

In the United States, cannabis remains a Schedule I substance at the federal level — a classification that carries the legal designation “no accepted medical use.” The DEA’s rescheduling process, which would move cannabis to Schedule III and loosen some research constraints, has been grinding through administrative proceedings for years without a clear timeline for completion.

The practical effect of Schedule I on research is significant. American scientists studying plant-derived cannabis face layers of federal restriction that simply don’t apply to studying dronabinol, which sits at Schedule III. The irony is not subtle: the synthetic copy of the plant molecule can be studied freely; the plant itself cannot.

This regulatory asymmetry is part of why the largest studies of whole-plant cannabis medicines are now coming out of Germany, Israel, and Canada — not the country with the most resources, the most sophisticated research infrastructure, and the largest population of elderly chronic pain patients in the world.

American seniors are turning to cannabis in growing numbers. They are doing so largely without the kind of rigorous clinical guidance that a study like this one is built to provide. Their doctors, in most states, still cannot recommend it through the Veterans Administration. Medicare does not cover it. And the federal research framework that could produce American-specific data on elderly cannabis patients remains constrained by a scheduling status written in 1970.

The Bottom Line

A 484-patient, 24-week study has now produced some of the clearest comparative data on cannabis-based pain treatment for elderly patients that exists anywhere. The plant-derived option outperformed the synthetic pharmaceutical version on pain, sleep, quality of life, and tolerability. The synthetic version left patients more likely to quit.

For an American senior managing chronic pain, this data is directly relevant to decisions they are making right now — often without their doctor’s guidance and without the support of their health insurance. The study is German. The population it speaks to is not.

Maya Torres covers the human side of cannabis policy for CannabisInquirer.com — expungement, equity, medical access, and the people the industry leaves behind.